• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.

作者信息

Srour Samer A, Olson Amanda, Ciurea Stefan O, Desai Parth, Bashir Qaiser, Oran Betul, Bose Prithviraj, Mehta Rohtesh, Patel Keyur P, Pemmaraju Naveen, Daver Naval, Verstovsek Srdan, Champlin Richard E, Popat Uday R

机构信息

The University of Texas MD Anderson Cancer Center.

The University of Texas Health Science Center at San Antonio.

出版信息

Haematologica. 2021 Jul 1;106(7):1988-1990. doi: 10.3324/haematol.2019.223503.

DOI:10.3324/haematol.2019.223503
PMID:31296578
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8252931/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2338/8252931/5ab594782685/1061988.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2338/8252931/5ab594782685/1061988.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2338/8252931/5ab594782685/1061988.fig1.jpg

相似文献

1
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.异基因干细胞移植后混合髓系嵌合体与骨髓纤维化复发
Haematologica. 2021 Jul 1;106(7):1988-1990. doi: 10.3324/haematol.2019.223503.
2
Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis.早期混合淋巴细胞供体/宿主嵌合现象与原发性或继发性骨髓纤维化患者移植结局改善相关。
Biol Blood Marrow Transplant. 2020 Dec;26(12):2197-2203. doi: 10.1016/j.bbmt.2020.07.013. Epub 2020 Jul 18.
3
Impact of Mixed Chimerism on Myelofibrosis Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.混合嵌合体对异基因造血干细胞移植后骨髓纤维化结局的影响。
Biol Blood Marrow Transplant. 2020 Dec;26(12):e301-e302. doi: 10.1016/j.bbmt.2020.09.003. Epub 2020 Sep 17.
4
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.异基因造血干细胞移植治疗骨髓纤维化
Blood. 2003 Dec 1;102(12):3912-8. doi: 10.1182/blood-2003-06-1856. Epub 2003 Aug 14.
5
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen.异基因造血干细胞移植治疗骨髓纤维化后完全供者嵌合体：预处理方案的作用。
Am J Hematol. 2021 Feb 1;96(2):234-240. doi: 10.1002/ajh.26042. Epub 2020 Nov 30.
6
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.异基因造血移植后的混合性T淋巴细胞嵌合现象可预测急性髓系白血病和骨髓增生异常综合征的复发。
Biol Blood Marrow Transplant. 2015 Nov;21(11):1948-54. doi: 10.1016/j.bbmt.2015.07.005. Epub 2015 Jul 14.
7
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.异基因干细胞移植后采用高灵敏度定量实时聚合酶链反应监测骨髓纤维化患者的JAK2-V617F突变
Blood. 2007 Feb 1;109(3):1316-21. doi: 10.1182/blood-2006-08-039909. Epub 2006 Oct 3.
8
Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation.监测异基因造血细胞移植后JAK2 V617F阳性骨髓纤维化患者的可测量残留病和嵌合状态。
Blood Cancer J. 2023 Jun 26;13(1):97. doi: 10.1038/s41408-023-00867-x.
9
Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution.异基因造血细胞移植治疗骨髓纤维化：单中心10年经验
Am J Hematol. 2010 Nov;85(11):904-7. doi: 10.1002/ajh.21851.
10
Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.成人急性淋巴细胞白血病异基因干细胞移植后用于复发预测的嵌合状态与微小残留病监测的比较
Biol Blood Marrow Transplant. 2014 Oct;20(10):1522-9. doi: 10.1016/j.bbmt.2014.05.026. Epub 2014 Jun 4.

引用本文的文献

1
Are transplant indications changing for myelofibrosis?骨髓纤维化的移植指征正在发生变化吗？
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):676-681. doi: 10.1182/hematology.2023000453.
2
Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation.监测异基因造血细胞移植后JAK2 V617F阳性骨髓纤维化患者的可测量残留病和嵌合状态。
Blood Cancer J. 2023 Jun 26;13(1):97. doi: 10.1038/s41408-023-00867-x.
3
Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine-First case report.

本文引用的文献

1
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.原发性骨髓纤维化中异基因干细胞移植的适应证和处理：由 EBMT/ELN 国际工作组达成的共识。
Leukemia. 2015 Nov;29(11):2126-33. doi: 10.1038/leu.2015.233. Epub 2015 Aug 21.
2
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.异基因造血移植后的混合性T淋巴细胞嵌合现象可预测急性髓系白血病和骨髓增生异常综合征的复发。
Biol Blood Marrow Transplant. 2015 Nov;21(11):1948-54. doi: 10.1016/j.bbmt.2015.07.005. Epub 2015 Jul 14.
3
阿扎胞苷联合口服地西他滨治疗异基因造血干细胞移植后复发的骨髓纤维化，供体嵌合率提高——首例报告
EJHaem. 2022 Nov 16;4(1):269-272. doi: 10.1002/jha2.611. eCollection 2023 Feb.
4
Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis.创新策略改善骨髓纤维化患者造血干细胞移植的结局。
Am J Hematol. 2022 Nov;97(11):1464-1477. doi: 10.1002/ajh.26654. Epub 2022 Jul 19.
5
2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management.2021 年异基因造血干细胞移植治疗骨髓纤维化的更新：当前数据在风险分层和管理方面的综述及应用。
Am J Hematol. 2021 Nov 1;96(11):1532-1538. doi: 10.1002/ajh.26349. Epub 2021 Oct 5.
6
Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis.早期混合淋巴细胞供体/宿主嵌合现象与原发性或继发性骨髓纤维化患者移植结局改善相关。
Biol Blood Marrow Transplant. 2020 Dec;26(12):2197-2203. doi: 10.1016/j.bbmt.2020.07.013. Epub 2020 Jul 18.
7
Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.早期移植后因素可预测骨髓纤维化患者接受异基因造血细胞移植的生存结局。
Blood Cancer J. 2020 Mar 10;10(3):36. doi: 10.1038/s41408-020-0302-9.
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
CALR 突变与 JAK2 突变、MPL 突变或三阴性骨髓纤维化的临床、细胞遗传学和分子比较。
Leukemia. 2014 Jul;28(7):1472-7. doi: 10.1038/leu.2014.3. Epub 2014 Jan 9.
4
Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.原发性骨髓纤维化患者的低强度造血细胞移植：来自国际血液和骨髓移植研究中心的队列分析。
Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97. doi: 10.1016/j.bbmt.2013.10.018. Epub 2013 Oct 23.
5
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.修订后的骨髓纤维化反应标准：国际工作组-骨髓增生性肿瘤研究和治疗（IWG-MRT）和欧洲白血病网络（ELN）共识报告。
Blood. 2013 Aug 22;122(8):1395-8. doi: 10.1182/blood-2013-03-488098. Epub 2013 Jul 9.
6
Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis.异基因干细胞移植替代骨髓纤维化患者的造血系统可促使骨髓纤维化迅速消退。
Fibrogenesis Tissue Repair. 2012 Jun 6;5(Suppl 1):S25. doi: 10.1186/1755-1536-5-S1-S25. eCollection 2012.
7
Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.供者淋巴细胞输注和二次移植作为减轻强度移植后复发骨髓纤维化的挽救治疗。
Br J Haematol. 2012 Oct;159(2):172-81. doi: 10.1111/bjh.12013. Epub 2012 Aug 22.
8
Guideline for the diagnosis and management of myelofibrosis.骨髓纤维化的诊断和管理指南。
Br J Haematol. 2012 Aug;158(4):453-71. doi: 10.1111/j.1365-2141.2012.09179.x. Epub 2012 Jun 1.
9
Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.动态国际预后评分系统评分、移植前治疗和慢性移植物抗宿主病决定了异基因造血干细胞移植治疗骨髓纤维化的预后。
Haematologica. 2012 Oct;97(10):1574-81. doi: 10.3324/haematol.2011.061168. Epub 2012 Apr 4.
10
Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.预测骨髓纤维化患者接受低强度移植后生存的风险模型。
Br J Haematol. 2012 Apr;157(1):75-85. doi: 10.1111/j.1365-2141.2011.09009.x. Epub 2012 Jan 27.